BioNTech Investor Day Presentation Deck
BNT311
Objective responses observed more frequently in PD-L1+ patients
Best relative change in sum
of diameters from baseline, %
40
20
-20
-60
Clinical activity by tumor PD-L1 status
in CPI-experienced patients with NSCLC (n=25)¹
PD-L1+ PD-L1-
11
Tumor reduction in 7/11
with PD-L1+ tumors
1 Among patients with evaluable baseline tumors. Fisher exact test odds ration for PD-L1+ vs PD-L1- tumors OR=0.11.
Data cut-off: September 21, 2021.
Ponce Aix S, et al. SITC Annual Meeting 2021; Poster presentation 516.
Y
Protein therapeutics
Preliminary findings in CPI-experienced patients with advanced NSCLC support enrichment based on tumoral PD-L1 status (TPS ≥1%)
A similar trend was observed in patients with UC, TNBC, and HNSCC
BIONTECH
121View entire presentation